Oral supplement containing hydroxytyrosol and punicalagin could help improve dyslipidaemia in an adult population without co-adjuvant treatment
According to recently published data from a randomised, double-blind, placebo-controlled study, supplementation with Euromed’s ingredient Pomalive, a precise combination of standardised olive and pomegranate fruits extracts, could help to improve dyslipidaemia, a condition resulting from an unbalanced distribution of different lipids (triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol), and a main risk factor in the development of cardiovascular diseases.
Researchers from the Nutrition Department, University Hospital La Paz (Madrid, Spain) found that oral intake of patent pending combined olives and pomegranate extracts (Pomalive) for 8 weeks (n=84) significantly reduced plasma triglycerides (p <0.05), decreased LDL-C (p <0.01) and increased HDL-C (p <0.05) in middle-aged participants with dyslipidaemia, without co-adjuvant treatment, and no adverse effects were observed.
Currently, statins are the most effective class of drugs for improving lipid profiles but up to 10% of patients experience side-effects that reduce compliance, thus limiting the risk reduction potential. Therefore, safe and effective alternatives are of great clinical interest.
This new publication further corroborates cardioprotective and antiatherosclerotic effects of combined hydroxytyrosol and punicalagin administration, as previously published.
According to the researchers, the described improvements in the plasma lipid profiles of dyslipidaemic subjects could contribute significantly to the improvement in endothelial dysfunction, arterial prehypertension and hypertension, as well as circulating plasma levels of oxLDL, as reported in 2019.
Pomalive is a patent pending precise combination of standardised polyphenols obtained from pomegranate and olive fruits.
Processed with an ecofriendly, water-only technology Pure-Hydro Process, it is free from contaminants, organic solvent residuals and toxins. The raw material of the selected fruits is grown locally in the Mediterranean region — close to the manufacturing plant — according to strict and transparent quality control protocols.
Andrea Zangara, Scientific Marketing Manager at Euromed, says: “In an increasingly ageing society fighting lifestyle diseases such ASCVD, we see our natural, sustainably produced and high-purity product as a real contribution to the enhancement of quality of life in later years."
"The study results, achieved using gold standard protocols and in collaboration with an authoritative medical institution, provide more evidence on the cardiovascular health-promoting benefits of Pomalive, making it an ideal inclusion in premium dietary supplements, functional foods and pharmaceuticals.”